{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:22:42Z","timestamp":1790108562702,"version":"4.0.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104692","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T15:51:17Z","timestamp":1767455477000},"page":"104692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effectiveness comparison of first-line CDK4\/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2"],"prefix":"10.1016","volume":"86","author":[{"given":"Giacomo","family":"Mazzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Dieci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pedersini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Sirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicla","family":"La Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Toss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fotia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"De Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ligorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Armani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Zurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Menichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Griguolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Faso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra Carnevale","family":"Schianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Munzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Chiappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Scagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pisegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Boldrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Berton Giachetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalissa","family":"Katrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Silvia","family":"Cona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Cantile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Grieco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Pirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zappulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Anna","family":"Rachele De Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vingiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Belfiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Sposetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bianchessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Miliziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea","family":"Iacobucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Fratini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secondo","family":"Folli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Baili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Scaperrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Depretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angioletta","family":"Lasagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Leli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Strina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Coccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Coviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.breast.2026.104692_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"issue":"20","key":"10.1016\/j.breast.2026.104692_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70061","article-title":"Lobular breast cancer statistics, 2025","volume":"131","author":"Giaquinto","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13058-015-0519-x","article-title":"Invasive lobular carcinoma of the breast: morphology, biomarkers and \u2019omics","volume":"17","author":"Reed","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"16","key":"10.1016\/j.breast.2026.104692_bib4","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1200\/JCO.2015.64.0334","article-title":"Genomic characterization of primary invasive lobular breast cancer","volume":"34","author":"Desmedt","year":"2016","journal-title":"J Clinic Oncol"},{"issue":"18","key":"10.1016\/j.breast.2026.104692_bib5","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/JCO.2007.14.9336","article-title":"Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials","volume":"26","author":"Pestalozzi","year":"2008","journal-title":"J Clinic Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2007.10.009","article-title":"Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes","volume":"44","author":"Rakha","year":"2008","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104692_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ejso.2013.02.007","article-title":"Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC)","volume":"39","author":"Biglia","year":"2013","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104692_bib8","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.annonc.2025.03.010","article-title":"Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+\/HER2\u2212 breast cancer and residual disease after neoadjuvant chemotherapy","volume":"36","author":"Loibl","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104692_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10549-016-3845-5","article-title":"Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis","volume":"157","author":"Di Meglio","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41523-022-00499-7","article-title":"Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies","volume":"8","author":"Mouabbi","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"20","key":"10.1016\/j.breast.2026.104692_bib11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2026.104692_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104692_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104692_bib14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.breast.2026.104692_bib15","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clinic Oncol"},{"issue":"25","key":"10.1016\/j.breast.2026.104692_bib16","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clinic Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"npj Breast Cancer"},{"issue":"10","key":"10.1016\/j.breast.2026.104692_bib18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.breast.2026.104692_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-Negative breast cancer that progressed on endocrine Therapy\u2014Monarch 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104692_bib21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2212 advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104692_bib22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with Palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clinic Oncol"},{"issue":"16","key":"10.1016\/j.breast.2026.104692_bib23","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall survival with palbociclib and fulvestrant in women with HR+\/HER2\u2212 ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2026.104692_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105309","article-title":"Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive\/HER2-negative advanced breast cancer in the PARSIFAL trial","volume":"10","author":"Llombart-Cussac","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104692_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.03.023","article-title":"Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study","author":"Provenzano","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s44276-024-00070-w","article-title":"Real-world effectiveness of CDK 4\/6 inhibitors in estrogen-positive metastatic breast cancer","volume":"2","author":"Gehrchen","year":"2024","journal-title":"BJC Rep"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.breast.2026.104692_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105570","article-title":"Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR-positive\/HER2-negative metastatic breast cancer in United States routine clinical practice","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104692_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104665","article-title":"Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+\/HER2\u2212 advanced breast cancer: a multicenter retrospective study","volume":"85","author":"Duchnowska","year":"2026","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.breast.2026.104692_bib30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/fon-2022-1287","article-title":"Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"19","author":"Kahraman","year":"2023","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104692_bib31","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/ijc.35296","article-title":"Head\u2010to\u2010head comparison of palbociclib and ribociclib in first\u2010line treatment of HR \u2010positive\/HER2 \u2010negative metastatic breast cancer with real\u2010world data from the OPAL registry","volume":"156","author":"Thill","year":"2025","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.breast.2026.104692_bib32","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.3390\/ijms24108488","article-title":"Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer","volume":"24","author":"Cejuela","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.breast.2026.104692_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1203684","article-title":"The effectiveness and safety of palbociclib and ribociclib in stage IV HR+\/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study","volume":"13","author":"Al-Ziftawi","year":"2023","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104692_bib34","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1177\/10781552231163121","article-title":"CDK4\/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset","volume":"29","author":"Buller","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"10.1016\/j.breast.2026.104692_bib35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN guidelines\u00ae insights: breast cancer, version 4.2023: featured updates to the NCCN guidelines","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"12","key":"10.1016\/j.breast.2026.104692_bib36","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104692_bib37","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"2","key":"10.1016\/j.breast.2026.104692_bib39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104692_bib40","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S1470-2045(21)00472-1","article-title":"Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4\/6 inhibitor plus fulvestrant: a US food and drug administration pooled analysis","volume":"22","author":"Gao","year":"2021","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.breast.2026.104692_bib41","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1158\/1078-0432.CCR-20-2268","article-title":"Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer","volume":"26","author":"Richard","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/mdy497","article-title":"Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer","volume":"30","author":"Sokol","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41523-020-00195-4","article-title":"The genomic landscape of metastatic histologic special types of invasive breast cancer","volume":"6","author":"Pareja","year":"2020","journal-title":"npj Breast Cancer"},{"issue":"23","key":"10.1016\/j.breast.2026.104692_bib44","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1158\/1078-0432.CCR-20-2268","article-title":"Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer","volume":"26","author":"Richard","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104692_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104316","article-title":"Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer","volume":"86","author":"Davis","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.breast.2026.104692_bib46","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104692_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104692_bib48","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/biom13091422","article-title":"An overview of the safety profile and clinical impact of CDK4\/6 inhibitors in breast cancer\u2014A systematic review of randomized phase II and III clinical trials","volume":"13","author":"Stanciu","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.breast.2026.104692_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102086","article-title":"Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer: a network meta-analysis","volume":"90","author":"Desnoyers","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.breast.2026.104692_bib50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cjp2.253","article-title":"Inter\u2010observer agreement for the histological diagnosis of invasive lobular breast carcinoma","volume":"8","author":"Christgen","year":"2022","journal-title":"The Journal of Pathology CR"},{"issue":"2","key":"10.1016\/j.breast.2026.104692_bib51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104692_bib52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ijc.33568","article-title":"Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting","volume":"149","author":"Kostos","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104692_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-85696-3","article-title":"Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands","volume":"11","author":"Cramer-van der Welle","year":"2021","journal-title":"Sci Rep"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:30:13Z","timestamp":1775683813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":53,"alternative-id":["S0960977626000020"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104692","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness comparison of first-line CDK4\/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104692"}}